KROS Stock Analysis: Buy, Sell, or Hold?
KROS - Keros Therapeutics, Inc. Common Stock
$11.10
-0.70 (-5.93%)
▼
5d:
+0.63%
30d:
+11.78%
90d:
-0.94%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
21d
Get Alerted When KROS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KROS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KROS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KROS is currently trading at $11.10, which is considered slightly high relative to its 30-day fair value range of $10.17 to $11.36.
Technical Outlook: Technically, KROS is in a downtrend. Immediate support is located at $10.57, while resistance sits at $12.19. Short-term momentum is weak, with the stock down 5.9% recently.
Market Sentiment: KROS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $21.83 (+96.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KROS is in a downtrend. Immediate support is located at $10.57, while resistance sits at $12.19. Short-term momentum is weak, with the stock down 5.9% recently.
Market Sentiment: KROS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $21.83 (+96.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$10.17 -
$11.36
Company Quality Score
58/100
(HOLD)
Options IV Signal
63th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
72.9%
All Signals
- NEUTRAL: Options fairly priced (IV 63th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.9%)
- BULLISH: Trading 96.7% below Wall St target ($21.83)
Trading Range Analysis
30-Day Trading Range
$10.17 -
$11.36
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$2.27
(20.4%)
Support & Resistance Levels
Support Level
$10.57
Resistance Level
$12.19
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.98
Wall Street Target
$21.83
(+96.7%)
Revenue Growth (YoY)
-99.8%
Profit Margin
-256.6%
Share & Embed Analysis
Last updated: July 14, 2026 6:15 AM ET
Data refreshes hourly during market hours. Next update: 7:15 AM
Data refreshes hourly during market hours. Next update: 7:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KROS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Jean Jacques Bienaime
BUY
1000 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 62 BUY |
Advanced KROS Option Strategies
Professional options setups generated by AI based on today's KROS price and gamma walls.
